The mortality burden of cachexia in patients with non-small cell lung cancer: A meta-analysis.

Authors

null

Philip D. Bonomi

Rush University Medical Center, Chicago, IL

Philip D. Bonomi , Jeffrey Crawford , Richard Francis Dunne , Eric J. Roeland , Karen E. Smoyer , Mohd K. Siddiqui , Thomas D. McRae , Michelle I. Rossulek , James H. Revkin , Lisa C. Tarasenko

Organizations

Rush University Medical Center, Chicago, IL, Duke Cancer Institute, Durham, NC, University of Rochester Medical Center, Rochester, NY, Oregon Health and Science University, Portland, OR, Envision Pharma Group, Philadelphia, PA, EBM Health Consultants, Delhi, India, Pfizer Inc., New York, NY, Pfizer Inc., Cambridge, MA

Research Funding

Pharmaceutical/Biotech Company
Pfizer

Background: Cachexia and weight loss have been linked to poor outcomes in patients with cancer. This study’s aim was to conduct a meta-analysis to estimate the risk of mortality associated with cachexia in patients with non-small cell lung cancer (NSCLC) in studies identified through a systematic literature review (SLR). Methods: A feasibility assessment was undertaken to determine the suitability of conducting a meta-analysis evaluating the impact of cachexia, defined per International Consensus criteria (ICC) or previous weight loss (WL) ≥5% (without specifying a 6-month duration), on overall survival (OS) in patients with NSCLC. The meta-analysis was conducted using a random-effects model, considering variability across studies, and using the identified studies as base case. The impact of heterogeneity was evaluated through sensitivity and subgroup analyses. Standard measures of statistical heterogeneity were calculated for each meta-analysis. Results: Of the 40 NSCLC publications identified in the SLR, 20 (50%) used the ICC definition or reported WL ≥5%. Sixteen studies (80%, n = 6,225 patients, published in 2016 to 2021) met the criteria for inclusion in the meta-analysis: 11 (69%) studies per ICC and 5 (31%) studies per WL ≥5%. Combined criteria (ICC or WL ≥5%) were associated with 82% higher mortality risk versus no cachexia or WL < 5% (pooled hazard ratio [95% CI]: 1.82 [1.47, 2.25]). A subgroup analysis of studies using the ICC definition (hazard ratio [95% CI]: 2.26 [1.80, 2.83]) or WL ≥5% (hazard ratio [95% CI]: 1.28 [1.12, 1.46]) showed consistent findings. Although high statistical heterogeneity (I-square = 88%) was observed across studies, this variability could be disregarded because effect estimates (hazard ratios) from included studies were directionally aligned with considerable overlap in CIs of individual studies. A meta-influence analysis did not identify any potential outliers. Results of the sensitivity and subgroup analyses were consistent with the base case analysis. Cumulative meta-analyses by publication year or data collection midpoint identified no time-varying effect, indicating results were robust to the differing timeframes of publication or data collection. No substantial publication bias, measured via funnel plot analysis, was identified in the meta-analysis. Conclusions: Based on thorough methodologic, clinical, and statistical heterogeneity assessments, the meta-analysis results are robust. ICC-defined cachexia or WL ≥5% were associated with inferior OS in patients with NSCLC. Identifying cachexia or WL ≥5% has important implications for prognosis and treatment of NSCLC.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Symptoms and Survivorship

Track

Symptom Science and Palliative Care

Sub Track

Late and Long-Term Adverse Effects

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr e24075)

DOI

10.1200/JCO.2023.41.16_suppl.e24075

Abstract #

e24075

Abstract Disclosures

Similar Abstracts

Abstract

2021 ASCO Annual Meeting

Anti PD-(L)1 in KRAS mutant advanced nsclcs: A meta-analysis of randomized controlled trials.

First Author: Thierry Landre

First Author: Jonathan N. Priantti

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Surrogate endpoints for overall survival in advanced hepatocellular carcinoma: A meta-analysis.

First Author: Yacob Saleh